These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27463681)

  • 1. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
    PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
    Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
    BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
    von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
    Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
    Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    Morizono A; Tanabe M; Ikemura M; Sasaki T; Ushiku T; Seto Y
    J Hum Genet; 2021 Aug; 66(8):785-793. PubMed ID: 33640902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
    Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
    Rice JC; Massey-Brown KS; Futscher BW
    Oncogene; 1998 Oct; 17(14):1807-12. PubMed ID: 9778046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-related mutations in the BRCA1 promoter in peripheral blood cells from cancer-free women.
    Al-Moghrabi N; Al-Qasem AJ; Aboussekhra A
    Int J Oncol; 2011 Jul; 39(1):129-35. PubMed ID: 21537840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer.
    Stefansson OA; Jonasson JG; Olafsdottir K; Hilmarsdottir H; Olafsdottir G; Esteller M; Johannsson OT; Eyfjord JE
    Epigenetics; 2011 May; 6(5):638-49. PubMed ID: 21593597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.